Mycobacterium Drug Resistance
Altered NADH:NAD+ mediate isoniazid/ethionamide coresistance in mycobacteria
Published in TB and Outbreaks Week, April 26th, 2005
According to recent research from the United States, "The front-line antituberculosis drug isoniazid (INH) and the related drug ethionamide (ETH) are prodrugs that upon activation inhibit the synthesis of mycolic acids, leading to bactericidal activity.
"Coresistance to INH and ETH can be mediated by dominant mutations in the target gene inhA, encoding an enoyl-ACP reductase, or by recessive mutations in ndh, encoding a type II NADH dehydrogenase (NdhII). To address the mechanism of resistance mediated by the latter, we have isolated novel ndh mutants of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Cryptosporidium Diagnostics
Immunomagnetic separation-PCR discriminates C. parvum and C. hominis - Enterobacter
Enterobacter cloacae outbreak strain produced VEB-3 beta-lactamase - HIV/AIDS Tuberculosis Coinfection
PCR useful when microbiological M. tuberculosis diagnosis inconclusive - Meningococcal Disease
Sequence variation in meningococci porB gene cause of New Zealand epidemic - Tuberculosis
Gatifloxacin does not kill M. tuberculosis during stationary growth phase - Adenovirus
Five new adenovirus type 37 strains caused epidemic keratoconjunctivitis - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
